Cost of cabozantinib

by E Soto-Perez-de-Celis 2024 Cited by 34The total cost incurred with cabozantinib treatment was $109,596 versus $39,741 with placebo plus best supportive care. Cabozantinib was not

Cabozantinib. Cabozantinib was approved by the FDA for the treatment of cost, when choosing which agents to use for the treatment of an individual

The total mean cost per patient was $56,621 for cabozantinib and $2024 for best supportive care in the German model resulting in incremental cost-effectiveness ratios for cabozantinib of $306,778

pERC deliberated upon the cost-effectiveness of cabozantinib compared with everolimus and axitinib and concluded that, at the submitted price

One-way sensitivity analysis suggested the cost of nivolumab, the discount rate, and the cost of cabozantinib had a great impact on the ICER. The cost-

Only direct medical costs were considered, including costs for cabozantinib, computed tomography, and management of grade 3-4 AEs (Table 1). The US cost of cabozantinib using the average wholesale price (AWP) in the Red Book,[19] was $10.93 per mg, the UK cost was $4.04 per mg,[20] and the

(cabozantinib) versus placebo in advanced pancreatic and extra cost containment; technological advances, new medicine and

by C McCrea 2024 Cited by 27related to costs (cost year, 2024) were disease manage- ment costs with nivolumab and cabozantinib in mind. This analysis may be extended to an

Results. Cabozantinib generated a gain of 0.18 life years (0.15 quality-adjusted life years) compared with best supportive care. The total mean cost per patient was $56,621 for cabozantinib and $2024 for best supportive care in the German model resulting in incremental cost-effectiveness ratios for cabozantinib of $306,778/life year and $375,470/quality-adjusted life year.